7-May-2024	Kazia Interview with Professor Sudha Rao from QIMR Berghofer Medical Research Institute

2-Feb-2024	Kazia Interview with Professor Matt Dun from the University of Newcastle, Australia

4-Dec-2023	2023 Kazia Therapeutics AGM

1-Nov-2023	Interview with Kazia CEO Dr John Friend regarding the Company’s intention to delist from the ASX

17-Jan-2023	Kazia Therapeutics CEO talks $4.5 million capital raise

5-Dec-2022	Kazia Therapeutics talks positive pre-clinical data for EVT801

16-Nov-2022	Kazia Therapeutics AGM 2022

8-Aug-2022	Kazia Therapeutics gives progress report on GBM AGILE pivotal study for glioblastoma

30-Jun-2022	Kazia Therapeutics Webinar - Combating Childhood Brain Cancer

8-Jun-2022	Kazia onto next chapter in Phase 2 brain metastases trial

17-May-2022	Interview with Dr Matt Dun for World DIPG Awareness Day

13-May-2022	Edison TV - Part 1 "Meet Kazia’s management team and hear about paxalisib"

13-May-2022	Edison TV - Part 2 "Paxalisib: Beyond glioblastoma and commercial opportunities"

13-May-2022	Edison TV - Part 3 "EVT801, capital markets and upcoming milestones"

2-May-2022	Kazia Therapeutics Ltd wraps up a busy quarter presenting paxalisib data at the AACR annual meeting

31-Jan-2022	Kazia presents at Edison Open House Global Healthcare 2022

12-Nov-2021	Kazia Therapeutics AGM 2021

8-Nov-2021	Kazia Therapeutics marks big step forward as first patient enrols in EVT801 cancer therapy trial

4-Nov-2021	Ticker News hears from Dr James Garner about Kazia's EVT-801 phase 1 clinical trial

26-Oct-2021	Edison TV: Kazia Therapeutics – introducing novel asset EVT-801

14-Sep-2021	Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

7-Sep-2021	CEO and Managing Director, Dr James Garner, presents at ShareCafe 3 September 2021

22-Jul-2021	Tickers News speaks to Kazia Therapeutics CEO James Garner About GBM Awareness Day

5-Jul-2021	CEO James Garner presents at Gold Coast Investment Showcase

20-May-2021	Edison TV: Kazia Therapeutics - overview and update with CEO James Garner

9-Feb-2021	Kazia Therapeutics with Proactive at the ASX Small and Mid Cap Conference

9-Apr-2020	Kazia CEO, Dr James Garner discusses the recent positive interim data from the phase II trial of paxalisib in glioblastoma, COVID-19 and the company's recent capital raising

26-Jun-2019	Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2019 Gold Coast Investment Showcase

15-Apr-2019	Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the Wholesale Investor Emergence event in Brisbane

11-Jul-2018	Kazia’s CEO Dr James Garner presented an overview of the company as a guest speaker at the 2018 Gold Coast Investment Showcase

6-Apr-2018	Dr James Garner speaks with CommSec re our GDC-0084 Phase II trial start

29-Mar-2018	NDF Research Senior Analyst Stuart Roberts interviews Kazia Therapeutics CEO Dr James Garner as the GDC-0084 phase II trial launches in the US

30-Nov-2017	CommSec interview re our new name, Kazia Therapeutics and our clinical trial progress

4-Jul-2017	CommSec Executive Series interviews CEO Dr James Garner on benefits of new business model for patients

1-May-2017	Dr James Garner, CEO, speaks to Canary Networks investment forum

31-Oct-2016	Sky News Interview – In-licensing of GDC-0084